DoH And UCSF Collaborate On Establishing Innovative Genome Surgery Centres In Abu Dhabi

The Department of Health – Abu Dhabi (DoH) has entered into a significant partnership with the University of California, San Francisco (UCSF) and the Innovative Genomics Institute (IGI). This collaboration aims to establish pioneering genome surgery centres in Abu Dhabi and California. The initiative seeks to advance genomic medicine and personalised genetic therapy, potentially transforming healthcare delivery worldwide.

Genome surgery is an experimental technique that modifies or replaces faulty genes to treat diseases. It uses advanced technologies like CRISPR for personalised genetic therapies. These new centres aim to diagnose and correct severe genetic conditions early, improving patient outcomes significantly. By leveraging CRISPR-based technologies, they offer customised interventions tailored to individual genetic mutations.

Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH, stated, "This collaboration reflects Abu Dhabi’s determination to pioneer real-world applications of advanced science. Partnering with UCSF and IGI would accelerate our ability to integrate genome-guided care into our healthcare system, creating an unprecedented opportunity to correct genetic conditions early in life." The partnership combines Abu Dhabi’s healthcare infrastructure with UCSF’s expertise in pediatric therapy and IGI’s research in gene editing.

Dr. Tippi MacKenzie from UCSF remarked on the potential of developing life-saving therapies for severe genetic conditions. She said, "We are excited by the possibility of developing mirrored programmes that coalesce multidisciplinary expertise and link the myriad steps between diagnosing a genetic disease and developing and implementing a safe genome surgery strategy." This collaboration aims to create innovative solutions for patients with rare and inherited diseases.

The partnership also focuses on training Emirati professionals in genomic surgery and clinical innovation. By intervening early in life-threatening conditions, it aims to reduce dependence on lifelong treatments and ease pressure on the healthcare system. This initiative strengthens Abu Dhabi’s position as a global hub for advanced genomic care.

Dr. Fyodor Urnov from IGI highlighted a recent achievement: "This year marks a landmark achievement for science and medicine of a CRISPR gene-editing therapeutic designed and administered on-demand to an infant with a severe inborn error of metabolism in record time." The IGI's collaboration with Danaher provides a foundation for scaling such therapeutic approaches globally.

Integrating Genomics into Public Health

This exploratory partnership aligns with Abu Dhabi’s vision to embed genomics into public health, focusing on personalised care. The Emirati Genome Programme has sequenced over 800,000 genomes, creating one of the most diverse national databases globally. Initiatives like the national pharmacogenomics reporting system help tailor treatment plans based on individual genetics.

Abu Dhabi introduced CRISPR-Cas9 gene-editing therapy through CASGEVY for sickle cell disease. Additionally, its Personalised Precision Medicine Programme has provided tailored oncology care to over 250 cancer patients. These efforts highlight Abu Dhabi’s commitment to advancing genomic solutions that improve health outcomes.

Strategic Mission to the United States

A high-level delegation led by DoH visited the U.S. from June 15-21, 2025. They conducted over 20 strategic meetings with public and private sector leaders aimed at knowledge exchange and investment opportunities. Key stakeholders included the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, NYUAD, Khalifa University, MBZUAI and startAD.

This mission underscores Abu Dhabi's dedication to adopting advanced health solutions through strategic partnerships and collaborations globally.

With inputs from WAM